Amgen Inc. (AMGN)
| Market Cap | 172.24B |
| Revenue (ttm) | 35.97B |
| Net Income (ttm) | 7.01B |
| Shares Out | 538.48M |
| EPS (ttm) | 12.93 |
| PE Ratio | 24.73 |
| Forward PE | 15.11 |
| Dividend | $9.52 (2.98%) |
| Ex-Dividend Date | Nov 21, 2025 |
| Volume | 5,486,162 |
| Open | 303.13 |
| Previous Close | 296.70 |
| Day's Range | 302.13 - 322.98 |
| 52-Week Range | 253.30 - 335.88 |
| Beta | 0.46 |
| Analysts | Hold |
| Price Target | 314.71 (-1.61%) |
| Earnings Date | Nov 4, 2025 |
About AMGN
Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. The company’s principal products include Enbrel for the treatment of rheumatoid arthritis, plaque psoriasis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet’s disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascul... [Read more]
Financial Performance
In 2024, Amgen's revenue was $33.42 billion, an increase of 18.57% compared to the previous year's $28.19 billion. Earnings were $4.09 billion, a decrease of -39.11%.
Financial StatementsAnalyst Summary
According to 15 analysts, the average rating for AMGN stock is "Hold." The 12-month stock price target is $314.71, which is a decrease of -1.61% from the latest price.
News
Amgen: Q3 Earnings Indicate Strong Emphasis On R&D
Amgen remains a compelling long-term buy, supported by robust R&D investment and a promising drug pipeline for future growth. AMGN delivered strong Q3 results, with double-digit revenue and volume gro...
Amgen Inc. (AMGN) Q3 2025 Earnings Call Transcript
Amgen Inc. ( AMGN) Q3 2025 Earnings Call November 4, 2025 4:30 PM EST Company Participants Casey Capparelli Robert Bradway - Chairman, CEO & President Peter Griffith - Executive VP & CFO Murdo Gordon...
Amgen Raises Full-Year Outlook After Third-Quarter Profit, Sales Jump
The biotechnology company reported a profit of $3.22 billion thanks to a 12% rise in product sales.
Amgen profit beats estimates, weight-loss data due by year-end
Amgen on Tuesday reported quarterly financial results that beat Wall Street expectations as product sales rose 12%, offsetting higher operating expenses related to experimental weight-loss drug MariTi...
AMGEN REPORTS THIRD QUARTER 2025 FINANCIAL RESULTS
THOUSAND OAKS, Calif. , Nov. 4, 2025 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced financial results for the third quarter of 2025.
AMGEN ANNOUNCES 2025 FOURTH QUARTER DIVIDEND
THOUSAND OAKS, Calif. , Oct. 31, 2025 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced that its Board of Directors declared a $2.38 per share dividend for the fourth quarter of 2025.
AMGEN'S LANDMARK PHASE 3 REPATHA DATA TO BE PRESENTED AS LATE BREAKER AT THE AMERICAN HEART ASSOCIATION SCIENTIFIC SESSIONS 2025
Repatha VESALIUS-CV Trial Met Dual Primary Endpoints Demonstrating Reduction in CV Events in High-Risk Patients Who Have Never Had a Heart Attack or Stroke Real-World Evidence from the Repatha-CE Tria...
AMGEN ANNOUNCES WEBCAST OF 2025 THIRD QUARTER FINANCIAL RESULTS
THOUSAND OAKS, Calif. , Oct. 29, 2025 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced that it will report its third quarter 2025 financial results on Tuesday, November 4, 2025, after the close of ...
Halper Sadeh LLC Encourages Amgen Inc. Shareholders to Contact the Firm to Discuss Their Rights
NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLC, an investor rights law firm, is investigating whether certain officers and directors of Amgen Inc. (NASDAQ: AMGN) breached their fiduciary duties to shareh...
US FDA expands use of Amgen, AstraZeneca's drug for sinus infection
The U.S. Food and Drug Administration has approved Amgen and AstraZeneca's drug for a type of chronic sinus infection, the drugmakers said on Friday.
FDA APPROVES TEZSPIRE® FOR CHRONIC RHINOSINUSITIS WITH NASAL POLYPS
Approval Broadens Indication for TEZSPIRE to a Second Disease Characterized by Epithelial-Driven Inflammation THOUSAND OAKS, Calif. , Oct. 17, 2025 /PRNewswire/ -- Amgen (NASDAQ:AMGN) and AstraZeneca ...
Healthy Returns: Amgen joins a growing list of drugmakers selling directly to consumers
Amgen is the latest drugmaker to sell certain drugs directly to consumers amid pressure from President Donald Trump. Meanwhile, Dr. Oz talks GLP-1s for obesity.
My Top 5 Biotech Stocks Big Pharma Could Buy Next
While AI hype reigns on Wall Street, the healthcare sector is still far from the peaks it reached during the COVID-19 pandemic. And what's more important, many of the biotech stocks remain outside of ...
Amgen Lowers Cholesterol-Medication Price After Trump Call for Price Cuts
The biotechnology company said that it has launched AmgenNow, a new direct-to-patient program, starting with its drug Repatha.
Amgen to sell cholesterol drug at 60% discount direct to US consumers
Amgen on Monday launched direct-to-consumer U.S. sales of its cholesterol medication Repatha at a discounted cash price, becoming the latest pharmaceutical company responding to U.S. political pressur...
AMGEN MAKES REPATHA® AVAILABLE THROUGH AMGENNOW, A DIRECT-TO-PATIENT PROGRAM IN THE U.S.
Eligible Patients Can Access Repatha at Nearly 60% Discount From the List Price THOUSAND OAKS, Calif. , Oct. 6, 2025 /PRNewswire/ -- Amgen (NASDAQ: AMGN) today announced the launch of AmgenNow, a new...
October Dogs Of The Dow Flash One Ideal 'Safer' Dividend Buy
Verizon stands out as the only Dow stock meeting the 'dogcatcher' ideal: annual dividends from $1K invested exceed its share price. Analyst forecasts suggest top-ten Dow Dogs could deliver average net...
Cramer's Stop Trading: Amgen
Jim Cramer breaks down why he's keeping an eye on shares of Amgen.
LANDMARK PHASE 3 TRIAL (VESALIUS-CV) MEETS PRIMARY ENDPOINTS IN A CARDIOVASCULAR PRIMARY PREVENTION STUDY OF 12,000 PATIENTS
Adding Repatha to Standard Therapy of Statins or Other LDL-C Lowering Treatments Significantly Reduces Cardiovascular Events Compared with Standard Therapy Alone Repatha is Now the First and Only PCSK...
‘Fast Money' traders talk opportunities in health care stocks
The Fast Money traders discuss why health care stocks look attractive on valuations, how underweight positioning could drive sustainability, why recent White House policy moves may be a “gift” to phar...
Amgen Shares Cross Above 200 DMA
In trading on Wednesday, shares of Amgen crossed above their 200 day moving average of $287.75, changing hands as high as $296.76 per share. Amgen shares are currently trading up about 5% on the day.
Many pharma companies already made U.S. investment promises, says Citi's Geoff Meacham
CNBC's “Closing Bell Overtime” team discusses President Trump's plan to impose a 100% tariff on “all any branded or patented Pharmaceutical Product” entering the U.S. with Geoff Meacham of Citi Resear...
Pharma tariffs still have a lot of questions outstanding, says Bernstein's Courtney Breen
Courtney Breen, Bernstein senior analyst, joins 'The Exchange' to discuss the companies exempt from pharma tariffs, the country's with existing trade deals and much more.